PRP4K is a HER2-regulated modifier of taxane sensitivity

References

• McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785:96-132; PMID:18068131
   PubMed Web of Science ®Google Scholar
• Lage H, Denkert C. Resistance to chemotherapy in ovarian carcinoma. Recent Results Cancer Res 2007; 176:51-60; PMID:17607916
   PubMedGoogle Scholar
• Choy H. Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol 2001; 37:237-47; PMID:11248579
   PubMed Web of Science ®Google Scholar
• Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324:485-9; PMID:2878368; http://dx.doi.org/10.1038/324485a0
   PubMed Web of Science ®Google Scholar
• Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32:S3-8; PMID:16360716; http://dx.doi.org/10.1053/j.seminoncol.2005.09.010
   PubMed Web of Science ®Google Scholar
• Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006; 97:813-20; PMID:16805818
   PubMed Web of Science ®Google Scholar
• Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917-31; PMID:9214671; http://dx.doi.org/10.1093/jnci/89.13.917
   PubMedGoogle Scholar
• Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003; 22:7280-95; PMID:14576838; http://dx.doi.org/10.1038/sj.onc.1206934
   PubMed Web of Science ®Google Scholar
• Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005; 102:8315-20.
   PubMed Web of Science ®Google Scholar
• Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004; 64:2502-8; PMID:15059905; http://dx.doi.org/10.1158/0008-5472.CAN-03-2013
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol Cancer Ther 2005; 4:1039-46; PMID:16020661; http://dx.doi.org/10.1158/1535-7163.MCT-04-0282
   PubMed Web of Science ®Google Scholar
• Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51-62; PMID:12559175; http://dx.doi.org/10.1016/S1535-6108(02)00235-0
   PubMed Web of Science ®Google Scholar
• Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003; 163:1109-16; PMID:12937152; http://dx.doi.org/10.1016/S0002-9440(10)63470-0
   PubMed Web of Science ®Google Scholar
• Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 14:8019-26; PMID:19088018; http://dx.doi.org/10.1158/1078-0432.CCR-08-0974
   PubMed Web of Science ®Google Scholar
• Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9:923-30; PMID:12631589
   PubMed Web of Science ®Google Scholar
• Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996; 13:1359-65; PMID:8808711
   PubMed Web of Science ®Google Scholar
• Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1997; 11:43-8; PMID:9110342
   PubMedGoogle Scholar
• Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004; 86:197-206; PMID:15567936; http://dx.doi.org/10.1023/B:BREA.0000036783.88387.47
   PubMed Web of Science ®Google Scholar
• Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96:1141-51; PMID:15292386; http://dx.doi.org/10.1093/jnci/djh198
   PubMedGoogle Scholar
• Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-13; PMID:15930421; http://dx.doi.org/10.1056/NEJMoa043681
   PubMed Web of Science ®Google Scholar
• Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496-506; PMID:17928597; http://dx.doi.org/10.1056/NEJMoa071167
   PubMed Web of Science ®Google Scholar
• Camerini A, Donati S, Viacava P, Siclari O, Puccetti C, Tartarelli G, Valsuani C, De Luca F, Martini L, Cavazzana A, et al. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res 2011; 30:38; PMID:21481270; http://dx.doi.org/10.1186/1756-9966-30-38
   PubMed Web of Science ®Google Scholar
• Dellaire G, Makarov EM, Cowger JM, Longman D, Sutherland HGE, Luhrmann R, Torchia J, Bickmore WA. Mammalian PRP4 Kinase Copurifies and Interacts with Components of Both the U5 snRNP and the N-CoR Deacetylase Complexes. Mol Cell Biol 2002; 22:5141-56; PMID:12077342; http://dx.doi.org/10.1128/MCB.22.14.5141-5156.2002
   PubMed Web of Science ®Google Scholar
• Schneider M, Hsiao HH, Will CL, Giet R, Urlaub H, Luhrmann R. Human PRP4 kinase is required for stable tri-snRNP association during spliceosomal B complex formation. Nat Struct Mol Biol 2010; 17:216-21; PMID:20118938; http://dx.doi.org/10.1038/nsmb.1718
   PubMed Web of Science ®Google Scholar
• Montembault E, Dutertre S, Prigent C, Giet R. PRP4 is a spindle assembly checkpoint protein required for MPS1, MAD1, and MAD2 localization to the kinetochores. J Cell Biol 2007; 179:601-9; PMID:17998396; http://dx.doi.org/10.1083/jcb.200703133
   PubMed Web of Science ®Google Scholar
• Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11:498-512; PMID:17560332; http://dx.doi.org/10.1016/j.ccr.2007.04.011
   PubMed Web of Science ®Google Scholar
• Duan Z, Weinstein EJ, Ji D, Ames RY, Choy E, Mankin H, Hornicek FJ. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther 2008; 7:2377-85; PMID:18687998; http://dx.doi.org/10.1158/1535-7163.MCT-08-0316
   PubMed Web of Science ®Google Scholar
• Gao Q, Mechin I, Kothari N, Guo Z, Deng G, Haas K, McManus J, Hoffmann D, Wang A, Wiederschain D, et al. Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 2013; 288:30125-38; PMID:24003220; http://dx.doi.org/10.1074/jbc.M113.473348
   PubMed Web of Science ®Google Scholar
• Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:913-20; PMID:8398031UND; http://dx.doi.org/10.1158/1055-9965.EPI-07-0692
   PubMed Web of Science ®Google Scholar
• Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6:459-69; PMID:15542430; http://dx.doi.org/10.1016/j.ccr.2004.09.027
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Chen GA, Reddy R, Tsai W, Schrump WD, Cole G, Jr., Schrump DS. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg 2004; 127:365-75; PMID:14762343; http://dx.doi.org/10.1016/j.jtcvs.2003.09.033
   PubMed Web of Science ®Google Scholar
• Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13:180-90; PMID:7799018
   PubMed Web of Science ®Google Scholar
• Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009; 122:2579-85; PMID:19625502; http://dx.doi.org/10.1242/jcs.039719
   PubMed Web of Science ®Google Scholar
• Letourneau IJ, Quinn MC, Wang LL, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, et al. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer 2012; 12:379; PMID:22931248; http://dx.doi.org/10.1186/1471-2407-12-379
   PubMed Web of Science ®Google Scholar
• Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, Butzow R. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004; 92:31-9; PMID:14751135; http://dx.doi.org/10.1016/j.ygyno.2003.10.010
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Amunni G, Villanucci A, Castiglione F, Rossi Degl'Innocenti D, Baroni G, Paglierani M, Taddei GL. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol 2006; 14:181-6; PMID:16785787
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84; PMID:16236738; http://dx.doi.org/10.1056/NEJMoa052122
   PubMed Web of Science ®Google Scholar
• Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sanchez-Rovira P, Ramos M, Rojo F, Burgues O, Carrasco E, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer 2014; 110:1139-47; PMID:24457911
   PubMed Web of Science ®Google Scholar
• Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30:1989-95; PMID:22493419; http://dx.doi.org/10.1200/JCO.2011.39.0823
   PubMed Web of Science ®Google Scholar
• Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392:300-3; PMID:9521327; http://dx.doi.org/10.1038/32688
   PubMed Web of Science ®Google Scholar
• Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer research 1990; 50:4087-91; PMID:1972347
   PubMed Web of Science ®Google Scholar
• Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoye N, Mes-Masson AM, Provencher DM, et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PloS One 2012; 7:e38541; PMID:22685580; http://dx.doi.org/10.1371/journal.pone.0038541
   PubMed Web of Science ®Google Scholar
• Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000; 102:1221-6; PMID:10982534; http://dx.doi.org/10.1161/01.CIR.102.11.1221
   PubMed Web of Science ®Google Scholar
• Bedard K, Attar H, Bonnefont J, Jaquet V, Borel C, Plastre O, Stasia MJ, Antonarakis SE, Krause KH. Three common polymorphisms in the CYBA gene form a haplotype associated with decreased ROS generation. Hum Mutat 2009; 30:1123-33; PMID:19388116; http://dx.doi.org/10.1002/humu.21029
   PubMed Web of Science ®Google Scholar
• Salsman J, Pinder J, Tse B, Corkery D, Dellaire G. The translation initiation factor 3 subunit eIF3K interacts with PML and associates with PML nuclear bodies. Exp Cell Res 2013; 319:2554-65; PMID:24036361; http://dx.doi.org/10.1016/j.yexcr.2013.09.001
   PubMed Web of Science ®Google Scholar